301 related articles for article (PubMed ID: 38362147)
1. Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review.
Mugiya T; Mothibe M; Khathi A; Ngubane P; Sibiya N
Front Pharmacol; 2024; 15():1355171. PubMed ID: 38362147
[TBL] [Abstract][Full Text] [Related]
2. Drug-induced disorders of glucose metabolism. Mechanisms and management.
Chan JC; Cockram CS; Critchley JA
Drug Saf; 1996 Aug; 15(2):135-57. PubMed ID: 8884164
[TBL] [Abstract][Full Text] [Related]
3. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
4. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.
Vos RC; van Avendonk MJ; Jansen H; Goudswaard AN; van den Donk M; Gorter K; Kerssen A; Rutten GE
Cochrane Database Syst Rev; 2016 Sep; 9(9):CD006992. PubMed ID: 27640062
[TBL] [Abstract][Full Text] [Related]
5. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
6. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
Roskoski R
Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
[TBL] [Abstract][Full Text] [Related]
7. Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia.
K Bhanumathy K; Balagopal A; Vizeacoumar FS; Vizeacoumar FJ; Freywald A; Giambra V
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33430292
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness of physical leisure time activities on glycaemic control in adult patients with diabetes type 2: A Systematic Review.
Pai LW; Chang PY; Chen W; Hwu YJ; Lai CH
JBI Libr Syst Rev; 2012; 10(42 Suppl):1-20. PubMed ID: 27820154
[TBL] [Abstract][Full Text] [Related]
9. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
10. Kinase inhibitors for cancer alter metabolism, blood glucose, and insulin.
Duggan BM; Marko DM; Muzaffar R; Chan DY; Schertzer JD
J Endocrinol; 2023 Feb; 256(2):. PubMed ID: 36476560
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
Chung C
J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of tyrosine kinase.
Klohs WD; Fry DW; Kraker AJ
Curr Opin Oncol; 1997 Nov; 9(6):562-8. PubMed ID: 9370078
[TBL] [Abstract][Full Text] [Related]
13. A historical overview of protein kinases and their targeted small molecule inhibitors.
Roskoski R
Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor beta-receptor (beta-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases.
Zaman GJ; Vink PM; van den Doelen AA; Veeneman GH; Theunissen HJ
Biochem Pharmacol; 1999 Jan; 57(1):57-64. PubMed ID: 9920285
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine Kinase Inhibitors and Diabetes: A Novel Treatment Paradigm?
Fountas A; Diamantopoulos LN; Tsatsoulis A
Trends Endocrinol Metab; 2015 Nov; 26(11):643-656. PubMed ID: 26492832
[TBL] [Abstract][Full Text] [Related]
16. Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the Treatment of Cancer: A Review.
Unnisa A; Chettupalli AK; Hussain T; Kamal MA
Anticancer Agents Med Chem; 2022; 22(20):3370-3381. PubMed ID: 35400324
[TBL] [Abstract][Full Text] [Related]
17. Current therapies and emerging targets for the treatment of diabetes.
Wagman AS; Nuss JM
Curr Pharm Des; 2001 Apr; 7(6):417-50. PubMed ID: 11281851
[TBL] [Abstract][Full Text] [Related]
18. Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.
Sakle NS; More SA; Dhawale SA; Mokale SN
Curr Drug Discov Technol; 2020; 17(5):585-615. PubMed ID: 31393251
[TBL] [Abstract][Full Text] [Related]
19. Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes.
Mokhtari D; Welsh N
Clin Sci (Lond); 2009 Nov; 118(4):241-7. PubMed ID: 19886867
[TBL] [Abstract][Full Text] [Related]
20. Cellular effects of small molecule PTP1B inhibitors on insulin signaling.
Xie L; Lee SY; Andersen JN; Waters S; Shen K; Guo XL; Moller NP; Olefsky JM; Lawrence DS; Zhang ZY
Biochemistry; 2003 Nov; 42(44):12792-804. PubMed ID: 14596593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
